Navigation Links
Brown cancer biologists identify major player in cell growth

When cells go about the business of dividing, they can get sidelined. Maybe there aren't enough nutrients. Maybe there aren't the right signals to resume multiplying. Either way, cells go quiet.

What can restart cell division -- the process that drives the development of embryos, the renewal of hair, skin and blood, and the creation of cancer -- is a single transcription factor called GABP, according to new research from The Warren Alpert Medical School of Brown University and Rhode Island Hospital.

The work, published online in Nature Cell Biology, introduces a new pathway that can be manipulated to control cell growth. Since cell growth is a fundamental biological process, the research may shed light on everything from miscarriages to muscular dystrophy. The main application, however, is cancer. Since a key characteristic of cancer cells is unchecked growth, the research identifies potential targets for new treatments.

"As a scientist and a physician, I am tremendously excited," said Alan Rosmarin, M.D., an associate professor in the Department of Medicine and the Department of Molecular Biology, Cell Biology and Biochemistry at Brown and director of clinical oncology research for Lifespan, Rhode Island's largest health care system. "This discovery not only adds to our basic understanding of cell division, it could lead to better cancer drugs. And they're needed. Cancer touches everyone."

During the cell cycle, the four-phase process of cell division, there is a period when the biochemical brakes are put on and cells become inactive. Then the process is kick-started and cells move into the so-called S phase, when DNA is duplicated. This is a critical juncture. If genes are missing or broken, these alterations are passed on to the new cell -- and could result in disability or in diseases such as cancer.

So biologists are keenly interested in identifying the accelerators that rev-up cell division. Ets transcription fact ors, a family of gene-regulating proteins that are major players in embryonic and cancer development, seemed obvious culprits. Rosmarin, a hematologist-oncologist, studies one member of the Ets family called GABP. This transcription factor helps make a variety of cells, including white blood cells. If those cells develop abnormally, leukemia results.

But the exact function of GABP in the cell cycle wasn't known. Rosmarin wanted to find out. So he and members of his laboratory created mice that carried a mutation -- tiny DNA sequences were inserted into their GABP-making gene. These DNA bits would serve as a time bomb of sorts, deleting a critical piece of the gene when given a chemical signal.

From these mice, Rosmarin and his team grew fibroblasts -- common connective tissue cells -- in a Petri dish with nutrient-rich serum and watched them grow. When they detonated their time bomb, GABP was disrupted, and the fibroblasts' ability to divide was dramatically reduced. At the same time, other genes known to restart cell division were unchanged.

The team confirmed GABP's critical role in cell growth another way. Simply forcing dormant cells to make GABP, they found, was enough to rouse cells from their slumber and get them to grow again.

"So we've found a new pathway to control cell growth," Rosmarin said. "Now that we know a way to disrupt GABP and stop division, there is the possibility that a drug can be made to do the same thing in cancer cells."
'"/>

Source:Brown University


Related biology news :

1. Brown-Harvard team solves mobile DNAs surgical sleight-of-hand
2. Prions rapidly remodel good protein into bad, Brown study shows
3. Brown seaweed contains promising fat fighter, weight reducer
4. Brown scientists map structure of DNA-doctoring protein complex
5. Brown team finds crucial protein role in deadly prion spread
6. Bones in motion: Brown scientists to create new 3-D X-ray system
7. Viral DNA sequence a possible trigger for breast cancer
8. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
9. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
10. Columbia research lifts major hurdle to gene therapy for cancer
11. Combination therapy boosts effectiveness of telomere-directed cancer cell death

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility ... Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will ... Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE mark ...
(Date:12/2/2016)... -- The Multiple Myeloma Research Foundation (MMRF) today announced that ... —the largest and most comprehensive study driving new genomic ... presented at the 58 th American Society of ... San Diego from December 3-6. The new ... as identify pathways and targets for new drug development. ...
(Date:12/2/2016)... 2016 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced the appointment of Earl Warren ... and private healthcare investor, to its Board of Directors. ... clinical and strategic experience at the highest level," said ... "As one of the world,s leading orthopedic surgeons, Dr. ...
(Date:12/2/2016)... Diego, CA (PRWEB) , ... December 01, 2016 , ... ... data from its Phase I/II clinical trials for AC0010 at the World Conference on ... forward to providing an update on the phase I/II clinical trials for AC0010 in ...
Breaking Biology Technology: